TELMISARTAN; HYDROCHLOROTHIAZIDE
Clinical safety rating: avoid
NSAIDs may diminish the antihypertensive effect Lithium levels may be increased Use in pregnancy can cause injury and death to the developing fetus.
Telmisartan is an angiotensin II receptor antagonist that selectively blocks the AT1 receptor, inhibiting the vasoconstrictor and aldosterone-secreting effects of angiotensin II. Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, reducing sodium and water reabsorption.
| Metabolism | Telmisartan: primarily metabolized by glucuronidation; minor CYP2C9 involvement. Hydrochlorothiazide: not significantly metabolized; eliminated renally. |
| Excretion | Telmisartan: predominantly biliary/fecal (≥97%), renal <1%. Hydrochlorothiazide: predominantly renal (≥95%) as unchanged drug. |
| Half-life | Telmisartan: ~24 hours (range 18–24 h), enabling once-daily dosing. Hydrochlorothiazide: 6–15 hours (average ~9 h); prolonged in renal impairment. |
| Protein binding | Telmisartan: ≥99.5%, primarily to albumin and α1-acid glycoprotein. Hydrochlorothiazide: 40–68%, primarily to albumin. |
| Volume of Distribution | Telmisartan: 500 L (≈7.1 L/kg for 70 kg), indicating extensive extravascular distribution. Hydrochlorothiazide: 3–5 L/kg, distributed in extracellular fluid. |
| Bioavailability | Telmisartan: oral bioavailability ~42–58%, dose-dependent; food slightly reduces absorption. Hydrochlorothiazide: oral bioavailability ~65–75%; food may increase absorption. |
| Onset of Action | Telmisartan: antihypertensive effect within 2–4 weeks of continuous therapy. Hydrochlorothiazide: diuresis begins within 2 hours, peak at 4–6 hours. |
| Duration of Action | Telmisartan: 24 hours, supporting once-daily dosing. Hydrochlorothiazide: 6–12 hours; antihypertensive effect may persist ≥24 hours with chronic dosing. |
| Molecular Weight | 514.57 |
Initial dose: 40 mg telmisartan/12.5 mg hydrochlorothiazide orally once daily. Titrate up to 80 mg telmisartan/25 mg hydrochlorothiazide once daily as tolerated.
| Dosage form | TABLET |
| Renal impairment | Contraindicated in anuria. For GFR 30-60 mL/min: caution due to thiazide efficacy; monitor electrolytes. For GFR <30 mL/min: not recommended for initial therapy; if used, monitor renal function and electrolytes. |
| Liver impairment | Child-Pugh A: No adjustment. Child-Pugh B: Maximum telmisartan dose 40 mg daily; avoid initiating combination. Child-Pugh C: Contraindicated. |
| Pediatric use | Safety and efficacy not established in pediatric patients. |
| Geriatric use | Initiate at lower dose (e.g., 40 mg/12.5 mg) and titrate slowly; monitor electrolytes, renal function, and orthostatic hypotension. |
| 1st trimester | Avoid. ACE inhibitors and ARBs are generally contraindicated in pregnancy. Hydrochlorothiazide use in first trimester may be associated with neural tube defects. |
| 2nd trimester | Avoid. Telmisartan is contraindicated due to risk of fetal renal dysfunction, oligohydramnios, and skull ossification defects. Hydrochlorothiazide may cause fetal electrolyte disturbances. |
| 3rd trimester | Avoid. Exposure in second and third trimesters is associated with fetal renal damage, oligohydramnios, and neonatal hypotension. Thiazides may cause neonatal thrombocytopenia, jaundice, and electrolyte imbalance. |
Clinical note
NSAIDs may diminish the antihypertensive effect Lithium levels may be increased Use in pregnancy can cause injury and death to the developing fetus.
| FDA category | Contraindicated |
| Placental transfer | Telmisartan crosses placenta; animal studies show fetal toxicity. Hydrochlorothiazide crosses placenta; detected in cord blood and amniotic fluid. |
■ FDA Black Box Warning
No black box warning.
| Common Effects | Hyperkalemia |
| Serious Effects |
Hypersensitivity to telmisartan or hydrochlorothiazidePregnancySevere renal impairment (CrCl <30 mL/min)AnuriaRefractory hypokalemia or hypercalcemiaConcomitant use with aliskiren in patients with diabetes mellitus
| Precautions | Avoid use in pregnancy (fetal toxicity), Monitor renal function and electrolytes, Hypotension in volume-depleted patients, Exacerbation of angioedema, Acute myopia/angle-closure glaucoma (with HCTZ), Electrolyte disturbances (hypokalemia, hyponatremia) |
| Food/Dietary | Avoid high-potassium foods (bananas, oranges, spinach) if telmisartan leads to hyperkalemia; but HCTZ may offset this. Limit sodium intake to enhance antihypertensive effect. Avoid grapefruit juice (may increase telmisartan absorption). |
Loading safety data…
| Breastfeeding | Telmisartan is excreted in animal milk; human data limited. Hydrochlorothiazide is excreted in breast milk in small amounts, may suppress lactation. Use only if clearly needed; monitor infant for hypotension, electrolyte disturbances, and dehydration. |
| Lactation Rating | L3 (Moderately safe) – Limited data; potential for adverse effects in infant. |
| Teratogenic Risk | First trimester: Limited data; potential risk of congenital malformations based on drugs acting on RAAS. Second and third trimesters: Fetal toxicity including oligohydramnios, fetal renal dysfunction, skull ossification defects, hypotension, and anuria. Hydrochlorothiazide may cause fetal or neonatal jaundice, thrombocytopenia, and electrolyte imbalances. |
| Fetal Monitoring | Monitor fetal growth, amniotic fluid volume, and fetal renal function via ultrasound. Assess maternal blood pressure, renal function, and serum electrolytes regularly. Monitor for signs of oligohydramnios or fetal distress. |
| Fertility Effects | No specific human studies; RAAS inhibitors may affect reproductive function in animal studies. Hydrochlorothiazide has no known significant fertility effects. |
| Clinical Pearls | Monitor serum potassium due to opposing effects of telmisartan (increases K+) and HCTZ (decreases K+); net effect often neutral but risk of hypo- or hyperkalemia exists, especially in renal impairment. Avoid in pregnancy (ARB + diuretic). Use with caution in volume-depleted patients; correct volume depletion prior to initiation. Telmisartan has PPAR-γ agonist activity, may improve insulin sensitivity. HCTZ dose >12.5 mg/day increases risk of electrolyte abnormalities and glucose intolerance. |
| Patient Advice | Take this medication exactly as prescribed, usually once daily. · Avoid pregnancy; use effective contraception. Stop drug immediately if pregnancy occurs. · Dizziness may occur, especially when starting treatment; avoid driving if affected. · Do not use salt substitutes containing potassium without consulting your doctor. · Report symptoms of electrolyte imbalance: muscle cramps, weakness, irregular heartbeat, excessive thirst. · Limit alcohol intake as it may increase blood pressure lowering effect. |